

Adavosertib

Catalog No: tcsc0105



Available Sizes

Size: 5mg

Size: 10mg

Size: 50mg

Size: 100mg



Specifications

CAS No:

955365-80-7

Formula:

$C_{27}H_{32}N_8O_2$

Pathway:

Cell Cycle/DNA Damage

Target:

Wee1

Purity / Grade:

>98%

Solubility:

DMSO : 18.75 mg/mL (37.46 mM; Need ultrasonic)

Alternative Names:

AZD1775;MK-1775

Observed Molecular Weight:

500.6


Product Description

Adavosertib (AZD-1775; MK-1775) is a potent **Wee1** inhibitor with an **IC₅₀** of 5.2 nM.

IC50 & Target: IC50: 5.2 nM (Wee1)

In Vitro: Adavosertib (MK-1775) enhances the cytotoxic effects of 5-FU in p53-deficient human colon cancer cells. Adavosertib (MK-1775) inhibits CDC2 Y15 phosphorylation in cells, abrogates DNA damaged checkpoints induced by 5-FU treatment, and causes premature entry of mitosis determined by induction of Histone H3 phosphorylation^[1]. Adavosertib (MK-1775) abrogates the radiation-induced G2 block in p53-defective cells but not in p53 wild-type lines^[2]. The combination of gemcitabine with Adavosertib (MK-1775) produces robust anti-tumor activity and remarkably enhances tumor regression response (4.01 fold) compared to gemcitabine treatment in p53-deficient tumors^[3].

In Vivo: In vivo, Adavosertib (MK-1775) potentiates the anti-tumor efficacy of 5-FU or its prodrug, capecitabine, at tolerable doses^[1]. Adavosertib (MK-1775) (60 mg/kg twice daily, p.o.) enhances H1299 xenograft tumor response to fractionated radiotherapy^[2]. Adavosertib (MK-1775) (30 mg/kg. p.o.) regresses tumor growth in PANC198, PANC215 and PANC185 as compared to GEM treated mice^[3].



All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!